Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: Historical development and future challenges
Similar content being viewed by others Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons in the brain and spinal cord leading to paralysis and eventually death, usually within 3 to 5 years of diagnosis
1 BI 3034701 is a potential first-in-class GLP-1/GIP/NPY receptor agonist designed to address obesity through three pathways, where neuropeptide Y2 (NPY2)-driven central control of hunger, appetite and food intake is complemented by GLP-1/GIP-mediated satiety, weight reduction, and metabolic regulation
In an in vitro study, the protective effects of GFST against alcohol hepatotoxicity in ethanol-exposed HepG 2 cells were revealed by preventing intracellular glutathione depletion, decreasing gamma-glutamyl transpeptidase activity, and suppressing cytochrome P450 2E1 enzyme expression [115]
MOTS-c, short for Mitochondrial Open Reading Frame of the 12S rRNA-c , is a peptide encoded not in nuclear DNA, but in mitochondrial DNA
Learn more about Low Dose Naltrexone as an alternative to GLP-1 injections
